Persistence of Antibodies against Diphtheria, Tetanus, Pertussis, and Poliovirus Types I, II, and III Following Immunization with DTaP Combined with Inactivated Wild-Type Polio Vaccine (DTaP-wIPV)
Authors:
- 31 January 2019
- journal article
- research article
- Published by Editorial Committee of Japanese Journal of Infectious Diseases, National Institute of Infectious Dis in Japanese Journal of Infectious Diseases
- Vol. 72 (1) , 49-52
Abstract
A follow-up serological study was conducted involving 47 subjects who received four doses of diphtheria and tetanus toxoids combined with acellular pertussis vaccine (DTaP) together with Salk-type inactivated polio vaccine (DTaP-wIPV) until 6 years of age. All antibody levels declined more rapidly than expected within 3 years after the completion of the primary vaccination with 4th booster dose and titers persisted until 6 years of age. The positive rate of the IgG antibody against pertussis toxin (PT) was 31.9% (15/47) at 4 years of age, 41.0% (16/39) at 5 years of age, and 40.5% (15/37) at 6 years of age. A significant increase in the PT antibody was observed in 6 subjects, suggesting subclinical infection. Positive rates of antibodies against other targets did not decrease but titers of neutralizing antibodies against poliovirus type III decreased in only a few subjects. These data suggest the need for an additional preschool booster immunization using DTaP-wIPV.Keywords
This publication has 19 references indexed in Scilit:
- Pertussis outbreak in university students and evaluation of acellular pertussis vaccine effectiveness in JapanBMC Infectious Diseases, 2015
- Duration of Pertussis Immunity After DTaP Immunization: A Meta-analysisPediatrics, 2015
- Genetic Analysis of Bordetella pertussis Isolates from the 2008–2010 Pertussis Epidemic in JapanPLOS ONE, 2013
- Vaccine chronicle in JapanJournal of Infection and Chemotherapy, 2013
- Ten years after polio eradication from the WPRO region: Current status and future problemsVaccine, 2012
- Poliovirus VaccineUirusu, 2012
- The epidemiology of pertussis in Germany: past and presentBMC Infectious Diseases, 2009
- Safety, reactogenicity and immunogenicity of a combined hexavalent tetanus, diphtheria, acellular pertussis, hepatitis B, inactivated poliovirus vaccine and Haemophilus influenzae type b conjugate vaccine, for primary immunization of infantsVaccine, 2004
- Development and clinical testing of multivalent vaccines based on a diphtheria–tetanus–acellular pertussis vaccine: difficulties encountered and lessons learnedVaccine, 2003
- Reemergence of Pertussis in the Highly Vaccinated Population of The Netherlands: Observations on Surveillance DataEmerging Infectious Diseases, 2000